Targeted screening of hip dysplasia in newborns: experience at a district general hospital in Scotland

Rahul Tyagi, Marcin R. Zgoda, Rachel Short
Department of Trauma and Orthopedic Surgery, University Hospital Crosshouse, Kilmarnock, Scotland, UK

Abstract

National Health Service Quality Improvement Scotland (NHS QIS) published a health technology scoping report in 2006 acknowledging that there are serious concerns within Scotland in relation to Developmental Dysplasia of Hip (DDH) as there is no formal screening program in place and there are significant variations between NHS boards leading to confusion for staff and parents. NHS QIS identified need for audit work to improve hip screening in Scotland. The aim of this study is review of current practice of selective screening for DDH. All newborns who had their first hip scan during one year period (2014) were included in this retrospective study and followed up until June 2015 to include any surgical intervention for dysplastic hip. Out of 428 babies (886 hip scans), abnormality was seen in 119 babies (47 hips) (134 Graf 2a/2b, 10 hips were 2c and 3 hips were Graf grade 3). Average age when first scan was performed was 5 weeks (range 3 weeks to 22 weeks). Analysis of risk factors in 119 babies with abnormal scan was consistent with literature (83 breech, 12 family history, 12 HBW, 10 instability and 2 twins of breech). Twelve babies (16 hips) required treatment and were successfully treated in Pavlik harness. There was one case of missed late dislocation, which lived outside catchment area for 3 years since birth. During this study period there was no case of avascular necrosis or femoral nerve palsy as a result of treatment. In our experience, selective hip screening by ultrasound scan is useful in avoiding overtreatment and minimizing late presentations.

Introduction

Since introduction of ultrasound scan for screening of hip dysplasia in 1980, incidence of hip dysplasia is reported to be around 7/1000 live births in Caucasians in comparison to 3.9/1000 in 1966 in Scotland. This variation could be due to different screening methods or due to variability in defining dysplastic hips. Breech presentation and family history are the two most common risk factors and National Institute of Clinical Excellence has included these two in Neonatal and Infant Physical Examination screening tool for dysplasia. In Aberdeen incidence of breech in dysplastic hips was 18%. Neonatal hip instability seem to resolve in vast majority of cases 5 days to 6 months following birth. For those who are treated with Pavlik harness or abduction brace, success rate have been reported be 80 to 100% depending on the age when treatment commenced and on the severity of dysplasia. Incidence of late presentation vary depending on the definition (3 weeks to 1 year). In Scotland it was reported to be 0.13/1000 in 1966 and 0.5/1000 in 2002 in Glasgow.

Screening program for hip dysplasia is a controversial issue and there is not current consensus on the best way to deal with it. German speaking countries follow universal screening but majority of health services offer selective screening of high-risk group. In England selective screening is in place, whereas in Scotland practice vary in different health boards. National Health Service Quality Improvement Scotland (NHS QIS) published a scoping report in 2006 and concluded that further audit work is necessary.

Background

University Hospital Crosshouse is a district general hospital providing pediatric orthopedic service for Ayrshire and Arran population in Scotland. There is hip dysplasia selective screening program in place and pathways for referral are shown in Figure 1. All newborns have physical examination at birth by a maternity care professional and subsequently by health visitor before 8 weeks. Some referrals are from general practitioner when there is a parental concern. Any hip abnormality picked up by these sources results in referral for an ultrasound scan which is performed by either a radiographer or the consultant radiologist, both trained in performing hip ultrasound scans by Graf static method. A senior orthopedic surgeon, who has special interest in this field supervised hip scan clinic and identified children who need follow up scans and treatment. Departmental protocol used in decision making for treatment of hip dysplasia is as follows: Graf 1 hips are discharged, Graf 2a are observed, Graf 2c are observed if presenting before 4 weeks and clinically stable otherwise treatment in pavlik harness is commenced. Graf 3 and 4 receive harness treatment in first instance and monitored closely by repeat scan. After 6-8 weeks treatment and when hip approaches near Graf type 1, harness is worn for 12 hours for another 4 to 6 weeks.
Results

In year 2014 there were 3618 live births in Ayrshire and Arran. After a total of 856 hip scans (428 babies) were reviewed. 147 hips (119 babies, 109 females and 10 males) were classified as abnormal. As this was review of selective screening, all patients with abnormal scan had one or more risk factors. There was no failure of treatment and none of them required surgical intervention. There was no complication from harness treatment and hip radiograph at 6 to 12 months of age showed acetabular index within 2 SD of mean for age.

The incidence of sonographic hip dysplasia was 32.89/1000, however incidence of dysplasia requiring treatment was 3.31/1000. There was one case of missed diagnosis. This 3-year-old girl was born outside catchment area and moved to Ayrshire at age of three. There was no history of high risk factors in her. Due to her social circumstances there was a delay in diagnosis and when she was reviewed at our clinic, diagnosis of hip dislocation was confirmed. An open reduction and de-rotation osteotomy was performed in first stage and she had satisfactory radiographs at 6 month follow up. Inclusion of this late diagnosis gave us incidence of 0.27/1000 for missed hip dysplasia in Ayrshire and Arran. Tables 2 and 3 presents characteristics of study group and treatment group respectively.

Discussion

In United Kingdom, selective high risk screening for dysplastic hips is in place in England. Public health England published guidance in 2014 and the program recommends selective ultrasound examination for babies with specific risk factors. The baby must receive an ultrasound examination of the hips if there is a family history of hip problems in early life and when the baby has been a breech presentation at or after 36 weeks of pregnancy.

In Scotland, there is wide variability in assessment of newborns after 72 hours and a review by Health Quality Improvement specifically mentioned the need for standardization of practice across Scotland.15

There is wide variability in reporting Developmental Dysplasia of Hip (DDH) due to difference in criteria used to diagnose and treat hip dysplasia. Late presentation of dysplastic hips vary from 3 weeks to 1 year, we consider Graf 2c or worse dysplastic hips presenting after age of 3 months as delayed presentation. Since introduction of selective screening, we are aware of only one study that looked at incidence of late diagnosis of dysplastic hips in Scotland. In this retrospective study, late diagnosis was considered when presentation was after 3 months, as nature of dysplastic hips was not defined it is difficult to draw any comparison. Authors noted no statistical difference in incidence (0.8/1000 before and 0.5/1000 after) of late presenting dysplasia before and after introduction of selective screening in Glasgow region. The incidence was calculated from only those cases that were born in the region (78 out of 539 late presentations). In our experience, we have seen 2 late presentations requiring surgical intervention on average in a year over last 4 years except for 2014 when we had only one late presentation. Several studies have shown that majority of missed dislocation patients did not have any risk factors7,18 and therefore it is unlikely that this incidence could be reduced by selective screening.

Current understanding is that only breech presentation and family history in first degree relatives should be considered for selective screening. Figures 1 and 2 suggest that sonographic dysplasia is prevalent in high risk groups and selective screening does identify those hips that could have presented late if left untreated initially. It is highly unlikely that late diagnosis can be completely avoided. Evidence from Norway, Austria and Germany suggest that a missed dislocation incidence of less than 0.5/1000 should be considered acceptable.19

There is no current evidence to support that early diagnosis and treatment with Pavlik harness improves long-term outcome. Majority of Graf 2a hips develops into mature hips (70-80%), type 2c does not always need treatment and can be observed if seen at 3-4 weeks of age.26 We observed that none of Graf 2a required any treatment which differ from finding of Itone and colleagues, where they reported that 2a (-) (50-54) should be treated in brace. All of the 16 hips (12 babies) treated with harness in our study responded to treatment and had acetabular index within 2SD of mean for their age at the time of 6-9 month follow up. We agree with Atalar and colleagues11 that early treatment affects outcome, in their study median age for first review was 8 weeks in comparison to our study where mean age was 5 weeks, hence difference in outcome.

Wahlen and colleagues21 reported on outcome at one year in 40 dysplastic hips treated with a modified abduction brace. They had overall 85% success in treating with a brace but 25% hips were Graf 2a. They had high rate

---

Table 1. Protocol for treatment of dysplastic hips.

| Graf type | Action        |
|-----------|---------------|
| 1         | Discharge     |
| 2a        | Follow up     |
| 2b        | Treat in harness |
| 2c        | Observe or treat in harness |
| 3         | Treat in harness |
| 4         | Harness/closed/open reduction |

Table 2. Distribution of risk factors and Graf type in studied population. In breech babies, 55 had unilateral 2a (55 Graf 2a hips), 24 were bilateral 2a (48 Graf 2a), 2 were bilateral 2c (4 Graf 2c hips) and 2 babies had 2c in one and 2a in the other hip.

| Risk Factors | Total number of babies referred | Abnormal scan (number of babies) | Graf 2a | Graf 2b | Graf 2c | Graf 3 |
|--------------|--------------------------------|----------------------------------|---------|---------|---------|--------|
| Breech       | 303                            | 83                               | 105     | 0       | 6       | 0      |
| Family history | 33                             | 12                               | 8       | 1       | 1       | 2      |
| HBW females | 24                             | 12                               | 12      | 0       | 0       | 0      |
| Twins        | 5                              | 2                                | 2       | 0       | 0       | 0      |
| CTEV         | 3                              | 0                                | 0       | 0       | 0       | 0      |
| Clinical concern | 60                           | 10                               | 4       | 2       | 3       | 1      |
| Combined numbers | 428                        | 119                              | 131     | 3       | 10      | 3      |
(33%) of persistent dysplasia above SD for age possibly due to delayed treatment (mean age at time of treatment commenced was 3.1 months) in comparison to our result of 100% success as our mean age when treatment was started was 6 weeks. Our results are in line with Peled and colleagues, who reported high success rate. Early start of the treatment and small number of cases may explain low failure rate. Our findings are very similar to that published by Clarke from Coventry in 1989, out of 4617, 10% babies had either clinical hip abnormality or had a risk factor but only 17 required treatment (3.7/1000). However rate of late dislocations remained unchanged (0.64/1000) and highlight the fact that zero percent late dislocation rate may never be achieved. We cannot exactly explain having no Graf IV hips in our cohort but incidence of Graf IV hips have been reported to be less than 0.05%, and out of 3618 live births theoretically there should be 1 to 2 Graf IV hips per year. It is possible that these may account for late presentations.

Conclusions
Due to ethical reasons we will probably never know the outcome of untreated but observed dysplastic hips in a large cohort of newborns; hence we should continue to offer selective screening with the aim of keeping incidence of late dislocations within acceptable range. Incidence of hip dysplasia requiring treatment and late presentation in our institute are similar to what has been reported in literature. We acknowledge the retrospective nature of our study and due to small number of patients in subgroups; statistical analysis was limited to descriptive nature. We are in process of reviewing data on prospective basis to analyze sufficient numbers of abnormal hips to achieve statistical significance.

Table 3. Graf type, age when scanned first and duration of treatment in 12 babies who were treated with Pavlik harness.

| Graf type       | Age (in weeks) when scanned first | Age (in weeks) when harness treatment started | Total duration of harness treatment |
|-----------------|----------------------------------|---------------------------------------------|-----------------------------------|
| 2b              | 12                               | 12                                          | 12                                |
| 2b              | 12                               | 13                                          | 14                                |
| 2b              | 13                               | 13                                          | 12                                |
| 2c (bilateral)  | 3                                | observed                                   |                                    |
| 2c (bilateral)  | 4                                | observed                                   |                                    |
| 2c              | 6                                | 6                                           | 10                                |
| 2c              | 7                                | 7                                           | 12                                |
| 2c              | 5                                | 5                                           | 10                                |
| 2c              | 5                                | 5                                           | 11                                |
| 2c (with other hip 2a) | 6       | 6                                           | 16                                |
| 2c (with other hip 2a) | 7       | 7                                           | 14                                |
| 3               | 4                                | 5                                           | 15                                |
| 3               | 3                                | 4                                           | 16                                |
| 3               | 6                                | 6                                           | 16                                |

Figure 1. Referral pathway for selective screening of suspected hip dysplasia.

Figure 2. Risk factors in babies with abnormal hip scan.
References

1. Graf R. The diagnosis of congenital hip joint dislocation by the ultrasound compound treatment. Arch Orthop Trauma Surg 1980;97:117-33.

2. Loder RT, Skopelja EN. The epidemiology and demographics of hip dysplasia. ISRN Orthop 2011;2011:238607.

3. Wynne-Davies R. A family study of neonatal and late-diagnosis congenital dislocation of the hip. J Med Genet 1970;7:315-33.

4. Population screening programmes collection. Newborn and infant physical examination: clinical guidance. Available from: https://www.gov.uk/government/collections/newborn-and-infant-physical-examination-clinical-guidance.

5. MacKenzie IG, Wilson JG. Problems encountered in the early diagnosis and management of congenital dislocation of the hip. J Bone Joint Surg Br 1981;63-B:38-42.

6. Hadlow V. Neonatal screening for congenital dislocation of the hip. A prospective 21-year survey. J Bone Joint Surg Br 1988;70:740-3.

7. Barlow TG. Early diagnosis and treatment of congenital dislocation of the hip. J Bone Joint Surg Br 1962;44:292-301.

8. Abdinejad F, Takapouy J, Eskandari N. Incidence of congenital dislocation of the hip in Shiraz. J Med Council Islamic Rep Iran 1996;9:275-80.

9. Iwasaki K. Treatment of congenital dislocation of the hip by the Pavlik harness. Mechanism of reduction and usage. J Bone Joint Surg Am 1983;65:760-7.

10. Atar D, Lehman WB, Tenenbaum Y, Grant AD. Pavlik harness versus Frejka splint in treatment of developmental dysplasia of the hip: bicenter study. J Pediatr Orthop 1993;13:311-3.

11. Atalar H, Sayli U, Yavuz OY, et al. Indicators of successful use of the Pavlik harness in infants with developmental dysplasia of the hip. Int Orthop 2007;31:145-50.

12. Marks DS, Clegg J, al-Chalabi AN. Routine ultrasound screening for neonatal hip instability. Can it abolish late-presenting congenital dislocation of the hip? J Bone Joint Surg Br 1994;76:534-8.

13. Kamath S, Mehdi A, Wilson N, Duncan R. The lack of evidence of the effect of selective ultrasound screening on the incidence of late developmental dysplasia of the hip in the Greater Glasgow Region. J Pediatr Orthop B 2007;16:189-91.

14. Public Health England: Guidance ultrasound examination of the hips in screening for DDH, 2014. Available from: https://www.evidence.nhs.uk.

15. Macpherson K. Screening hips of newborns in Scotland: a Health Technology Assessment scoping report. Glasgow: Quality Improvement Scotland (NHS QIS). 2006 Screening hips of newborns in Scotland: HTA report.

16. Information Services Division: Births in Scottish hospitals. Available from: http://www.isdscotland.org.

17. Nunag P, Duncan R, Wilson N. Ultrasound screening for developmental dysplasia of the hip without orthopaedic examination: its effect on the incidence of late diagnosed cases. J Bone Joint Surg Br 2009;91-B.

18. Clarke NM, Clegg J, Al-Chalabi AN. Ultrasound screening of hips at risk for CDH. Failure to reduce the incidence of late cases. J Bone Joint Surg Br 1989;71:9-12.

19. Ihme N, Altenhofen L, von Kries R, Niethard FU. [Hip ultrasound screening in Germany. Results and comparison with other screening procedures]. Orthopade. 2008;37:541-548. [Article in German]

20. Omerolu H, Caylak R, Inan U, Köse N. Ultrasonographic Graf type IIa hip needs more consideration in newborn girls. J Child Orthop 2013;7:95-8.

21. Wahlen R, Zambelli PY. Treatment of the developmental dysplasia of the hip with an abduction brace in children up to 6 months old. Adv Orthop 2015;2015:103580.

22. Peled E1, Bialik V, Katzman A, et al. Treatment of Graf’s ultrasound class III and IV hips using Pavlik’s method. Clin Orthop Relat Res 2008;466:825-9.

23. Peled E, Eidelman M, Katzman A, Bialik V. Neonatal Incidence of hip dysplasia: ten years of experience. Clin Orthop Relat Res 2008;466:771-5.